Explore published research on ptsd, including study methods and limitations.
Study of Nigerian army veterans from peacekeeping operations found 22% had PTSD, which was significantly associated with longer deployment, alcohol use, and lifetime cannabis use.
Among 432 male veterans, less PTSD improvement during treatment predicted greater cannabis use at 4 months, specifically linked to avoidance/numbing and hyperarousal symptoms.
Structured interviews revealed cannabis use disorders and PTSD were significantly underdiagnosed in VA medical records for 84 military veterans.
Veterans with poor perceived sleep quality reduced their cannabis use less during a 6-month quit attempt, even after accounting for PTSD and withdrawal.
Cannabis-dependent veterans with PTSD used cannabis more for coping, experienced worse withdrawal, and had stronger cravings than veterans without PTSD.
Among 54 South African border war veterans, 33% had PTSD, and current cannabis use was the only substance significantly linked to PTSD despite high resilience.
Population study of 1,560 young adults found lifetime crack cocaine use (2.5% prevalence) was associated with PTSD, antisocial personality disorder, suicide risk, and polysubstance use including cannabis.
Review of evidence across 13 state-approved medical marijuana conditions found insufficient evidence for most, with the strongest support for chronic pain and muscle spasticity.
Review of 11 studies found veterans with PTSD use cannabis for coping, with small studies suggesting sleep and nightmare improvements, but controlled trials are needed.
Among 104 cannabis-dependent veterans, PTSD predicted higher baseline use and slower initial reduction after a quit attempt, but did not affect relapse timing.
Veterans of Iraq and Afghanistan described cannabis as more effective and less problematic than alcohol or prescriptions for PTSD, with coping patterns ranging from approach to avoidance.
In 116 veterans attempting cannabis cessation, PTSD symptoms predicted declining friend support over 6 months, but only among those who relapsed in the first month.
Study of 3,233 veterans finding cannabis use disorder independently associated with 2.3 times higher odds of suicide attempts, even after controlling for PTSD, depression, and other substance use.
Review proposing that the endocannabinoid system influences dream activity, supported by its known roles in consciousness, emotion, and sleep, and by preliminary evidence of cannabinoid-related nightmare reduction in PTSD.
Rat study found CBD disrupted fear memory consolidation when injected into the prefrontal cortex 5 hours (but not immediately) after fear learning, reducing dopamine activity and memory gene expression.
The biology linking the endocannabinoid system to PTSD was strong, but clinical evidence for cannabis as treatment was weak. Nabilone showed real promise for nightmares specifically.
Rat study showing CBD disrupted both specific and generalized fear memory consolidation through anandamide-mediated CB1 and CB2 receptor activation in the dorsal hippocampus.
Comprehensive review cataloged six approved cannabinoid medications and evidence across pain, epilepsy, cancer, neurodegeneration, PTSD, anxiety, and addiction, spanning the full endocannabinoid system.
Review mapping how blood endocannabinoid levels shift with exercise, sleep, stress, pain, and metabolism — showing why cannabis affects so many different systems.
Cannabis use disorder was the only factor consistently associated with self-injury across all models in Iraq/Afghanistan veterans, with odds ratios of 3.10 for suicidal and 5.12 for nonsuicidal self-injury.
Study of 459 SUD patients found a graded pattern: childhood trauma plus PTSD showed the worst cannabis and psychiatric outcomes, trauma-only was intermediate, and no-trauma had the best outcomes.
Among 319 Iraq/Afghanistan veterans, cannabis dependence was associated with nearly 8-fold increased odds of post-deployment suicide attempts, independent of PTSD, depression, and other substance use.
In a year-long study of 545 at-risk military personnel, marijuana use combined with high PTSD symptoms predicted worsening PTSD and increased suicidal behavior, an interaction not seen with alcohol or opioids.
A Lancet meta-analysis of 83 studies found scarce evidence that cannabinoids help depression, anxiety, PTSD, or other mental disorders, with THC products doubling adverse event rates versus placebo.
Systematic review of 14 RCTs (1,629 participants) finds cannabis-based medicines improved symptoms across multiple mental disorders as adjuncts but achieved no remissions, with larger trials needed.
Review of animal and human studies finds cannabinoid-facilitated extinction of traumatic memories with large effect sizes, acting through prefrontal cortex, amygdala, and hippocampus.
Survey of 93 veterans with free cannabis access found most used it to substitute for other substances, but chose high-THC products without clinical guidance.
Systematic review of cannabis for PTSD through 2019 found promising signals for nabilone and nightmares, but most evidence remained low-quality and the broader case unproven.
PET brain imaging found altered CB1 receptor binding across cannabis use disorder, alcohol use disorder, schizophrenia, PTSD, and eating disorders.
A review found suggestive evidence that CBD may reduce anxiety and fear responses in PTSD, but cannabis use may worsen depression. Well-designed randomized trials remain largely absent across these conditions.
A review found preliminary evidence that cannabis may help PTSD patients and reduce use of more harmful drugs, but rigorous clinical trials are needed to establish whether cannabis-based medicines should be integrated into treatment.
A nationwide VA study of 1,413 veterans found cannabis co-use was not associated with meaningful reductions in opioid use or PTSD symptoms, challenging policy rationales for cannabis as a PTSD treatment or opioid substitute.
Among veterans with cannabis use disorder, 79% had a co-occurring mental health disorder and 77% had another substance use disorder, with comorbid conditions driving greater mental health service use.
Systematic review of 10 studies found cannabinoids may reduce PTSD symptoms, especially sleep disturbances and nightmares, but all evidence was of low quality with only one controlled trial.
Rat study found endocannabinoid-boosting drugs reduced persistent fear after predator stress through CB2 (not CB1) receptors, with CB2 gene expression upregulated in the prefrontal cortex by stress.
Focus group of 7 veterans with chronic PTSD found they used medical cannabis for symptom management (especially sleep), not intoxication, with stigma as a major barrier.
Canadian national survey of 24,089 people found cannabis use was associated with a weaker link between PTSD and both severe depression and suicidal ideation.
First clinically-focused systematic review found CBD tentatively supported for social anxiety and adjunctive schizophrenia, with high-THC showing no depression benefit.
A CB1 agonist reduced anxiety but not conditioned fear in rats modeling PTSD, suggesting endocannabinoid drugs may help with PTSD-related anxiety without erasing fear memories.
The first placebo-controlled trial of smoked cannabis for PTSD in 80 veterans found all groups improved, but no cannabis preparation outperformed placebo over three weeks. The strong placebo response complicates interpretation.
Study of 3,157 veterans found cannabis use and cannabis use disorder were associated with 1.5 to 8.3 times higher odds of psychiatric conditions, suicidality, and treatment utilization.
Systematic review found only 8 small RCTs testing cannabinoids for depression, anxiety, or PTSD, with insufficient evidence to recommend cannabis for any of these conditions.
Review of 86 studies found cannabis use in veterans consistently linked to other substance use, psychiatric disorders, and self-harm, with almost no studies testing therapeutic benefits.
Study of 215 Israeli combat veterans found moral injury was linked to cannabis use disorder through depression, with social support unexpectedly failing to protect against this pathway.
Among Israeli combat veterans, depression (AOR 1.98) but not PTSD independently predicted cannabis dependence, challenging assumptions about PTSD-driven cannabis use in military populations.
CBD disrupted fear memory reconsolidation in rats through CB1 receptors in the anterior cingulate and prelimbic cortex, not the infralimbic cortex.
Survey of 1,230 veterans found those who co-used tobacco and cannabis had significantly higher stress, PTSD, depression, and anxiety than single-substance users.
CBD disrupted fear memory reconsolidation in female rats through hippocampal CB1 receptors, reducing fear behavior for over a week without reinstatement.
Combining stress hormones with a CB1 blocker turned normal fear memories into intense, generalized ones resembling traumatic memories in rats.
Among 608 US veterans with PTSD, frequent cannabis users were 3-4x more likely to have depression, anxiety, and suicidal ideation, and 8-12x more likely to rely on avoidance coping.
Longitudinal study of 361 veterans found cannabis use predicted worsening PTSD intrusion symptoms at 6 months, while PTSD predicted cannabis use disorder at 12 months, suggesting a harmful cycle.
Systematic review of 15 studies found cannabis use associated with aggression in PTSD and psychotic disorders, but causal conclusions cannot be drawn due to methodological limitations.
Real-time tracking of 62 psychiatrically hospitalized teens found cannabis use boosted positive mood and reduced anger, with stronger effects in youth with PTSD or anxiety disorders.
A 30-day experience sampling study of 145 women experiencing intimate partner violence found PTSD externalizing and arousal symptoms linked to same-period cannabis use but not future use.
A review of purified CBD clinical trials found the strongest evidence for anxiety (17 RCTs), psychosis (8 RCTs), PTSD (4 RCTs), and substance abuse (3 RCTs), but not for pain or sleep.
First case report of cannabis-assisted psychotherapy for dissociative PTSD showed dramatic improvement over 10 sessions, drawing parallels to psychedelic-assisted therapy.
Survey of 415 Canadian military members and veterans at a mental health clinic found cannabis use was common, associated with younger age and PTSD.
EWAS in 2,310 veterans found four DNA methylation sites linked to cannabis use disorder independent of smoking, with the CUD-PTSD combination producing amplified epigenetic changes beyond either condition alone.
Prospective study of 2,943 trauma survivors found PTSD symptoms predicted increased substance use over time — with prior trauma and demographics determining who was most vulnerable.
In 404 trauma-exposed college students, restricted access to rewarding activities (not inability to feel pleasure) fully explained the link between PTSD symptoms and cannabis misuse.
Meta-analysis of 4 RCTs found cannabis users with PTSD still benefited from trauma-focused therapy, but attended fewer sessions and showed less improvement in other substance use.
A study of 1,618 trauma-exposed civilians found that heavy cannabis and alcohol users had worse PTSD and depression symptoms, with all groups peaking at 8 weeks posttrauma.
Clinical review finds growing evidence for cannabinoids in autism, Tourette syndrome, anxiety, and PTSD, with practical dosing: start 1-2.5 mg THC/day, target 10-20 mg.
Systematic review of 14 studies found mixed evidence for cannabis in PTSD overall, but possible benefits for re-experiencing and arousal symptoms. CUD patients consistently showed worse outcomes.
Cannabis use disorder worsens PTSD through psychological inflexibility — rigid, avoidant thinking that prevents trauma processing — a mechanism that's treatable with targeted therapy.
In 183 veterans treated for PTSD + substance use, ongoing cannabis use didn't predict worse PTSD symptoms or dropout at subsequent assessments — though concurrent heavy drinking was associated with worse symptoms.
3-month daily diary study of 74 veterans: cannabis use predicted lower next-day stress, which predicted fewer PTSD symptoms and better sleep quality.
Veterans daily diary: cannabis linked to same-day lower stress and better sleep with no next-day effects. Poor sleep drives next-day stress and alcohol use.
Brain scans of 27 cannabis users with trauma histories showed that trauma reminders increased cannabis craving and activated reward circuits, revealing a potential neural pathway from trauma to problematic cannabis use.
In nearly 3,000 trauma survivors, household income modified the relationship between PTSD symptoms and substance use, influencing whether people turned to tobacco, alcohol, or cannabis.
Israeli patients using medical cannabis for pain or PTSD described elaborate coping strategies for adverse effects and social stigma, including concealment, identity management, and building patient communities.
A new brief therapy combining trauma writing with cannabis coping skills showed early promise in three young women after sexual assault—but needs rigorous testing.
Rat study found THC+CBD use caused stress responses to generalize to neutral stimuli via astrocyte changes in the nucleus accumbens, but only in males.
In a rat PTSD model, CBD did not significantly reduce anxiety but improved spatial memory and reduced brain oxidative stress, suggesting neuroprotective rather than directly anxiolytic effects.
PET imaging of 62 participants found CB1 receptor availability was not different in PTSD overall but was significantly linked to emotional numbing symptoms, suggesting a specific endocannabinoid role.
A review found insufficient evidence for cannabis in PTSD treatment, while Polish medical marijuana clinic websites marketed it aggressively as a therapy.
A mobile app successfully collected real-time passive and active data from 95 veterans with PTSD and cannabis use over 3 months, with 92% passive and 68% active data rates.
A review found the endocannabinoid system regulates fear and extinction learning in PTSD, with preliminary evidence that cannabinoid-based treatments like nabilone can help, though self-medication carries risks.
CBD given during repeated social stress in mice prevented social avoidance and enhanced cocaine vulnerability while normalizing serotonin, endocannabinoid, and stress hormone gene expression.
Study of 257 women found cannabis use during pregnancy independently predicted higher postpartum PTSD and depression, separate from the effects of intimate partner violence.
Survey of 544 SUD treatment patients found cannabis use linked to more trauma and psychiatric diagnoses, but trauma may explain the cannabis-mental health connection.
A review found consistent preclinical evidence that endocannabinoid modulation can improve PTSD-related behaviors, but human research remains mixed and insufficient to support clinical cannabinoid therapy for PTSD.
Ontario data showed cannabis involvement in PTSD emergency visits rose 151% during cannabis liberalization (2008-2022), outpacing alcohol's 58% increase.
Study of 105 adolescent psychiatric patients found that distorted time perspective mediated the link between trauma and PTSD severity, with PTSD symptoms in turn predicting cannabis use.
Men with PTSD showed depleted endocannabinoid levels while women showed elevated inflammatory markers, suggesting PTSD operates through different biological mechanisms by sex.
Meta-analysis of 21 RCTs found pharmaceutical-grade CBD (SMD -0.61) and THC (SMD -0.65) showed moderate effects for anxiety disorders and PTSD, while CBD-THC mixtures did not reach significance.
Combining low-dose CBD with resveratrol or alpha-lipoic acid matched high-dose CBD for reducing aggression and depression in PTSD-model mice, though anxiety was unaffected.
Systematic review of 57 studies found that 70% of the highest-quality research reported improvements in anxiety disorders with medicinal cannabis, though reporting standards remain a major issue.
Large prospective study of 2,449 trauma survivors found pre-trauma insomnia predicted heavier cannabis and alcohol use 8 weeks later, partly through early PTSD symptoms.
Two randomized trials found CBD up to 1200mg/day was tolerable but no better than placebo for alcohol use disorder or co-occurring PTSD, despite both groups showing large improvements.
Systematic review of 11 studies found 3-21% of people with anxiety disorders also have cannabis use disorder, with rates potentially reaching 34% among veterans with PTSD.
Scoping review of RCTs found thin and mixed evidence for cannabis treating mental health conditions — CBD shows some anxiety promise but most psychiatric evidence remains inconclusive.
87-day daily diary study of 74 veterans found cannabis predicted less next-day depression for veterans without PTSD, but this mood benefit disappeared in veterans with PTSD — complicating the self-medication narrative.
Experimental study found that among trauma-exposed cannabis users, negative thoughts about oneself — but not self-blame or negative world views — specifically drove cannabis cravings after trauma cue exposure.
Study of 238 deployed military finds PTSD specifically drives cannabis use, while combat exposure and moral injury drive prescription drug misuse — distinct pathways requiring different interventions.
Rat study finds single cannabis vapor exposure before fear learning prevents fear memory return two weeks later in both sexes, with opposite effects on extinction learning between males and females.
Trauma patients who tested positive for THC on admission were 66% more likely to screen positive for post-traumatic stress symptoms.
Systematic review of 38 studies finds integrated CBT works for CUD with co-occurring conditions, and AI tools can enhance contingency management.
Study in female rats finds CB1 activation reduces acute fear but may impair fear extinction, with important implications for cannabis use in PTSD treatment.
Pilot study found veterans with PTSD who achieved 12 weeks of cannabis abstinence saw 71% symptom reduction vs. 37% in those who continued using.
Two samples of veterans (N=741 total) showed that cannabis use didn't undermine intensive PTSD treatment — users and non-users improved similarly.
Study of 1,992 Canadian veterans found regular cannabis users had 2-4 times the odds of chronic pain, mental disorders, and suicidal ideation, but also 5.6 times the odds of seeking professional help.
Nabilone significantly reduced PTSD nightmares in 10 treatment-resistant military veterans, leading the Canadian Armed Forces to adopt cannabinoids for PTSD treatment.